Cite

HARVARD Citation

    Xipell, M. et al. (2018). Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology. p. . [Online]. 
  
Back to record